Causal Effect of Coenzyme Q10 Nutrition and Cognitive Dysfunction in the Metabolic Storm (Hyperglycemia and Sarcopenia) and Brain-derived Neurotrophic Factor

Not Applicable

Recruiting

• Conditions: Alzheimer Disease; Pre-sarcopenia; Mild Cognitive Impairment; Hyperglycemia
• Interventions: Other: Placebo; Dietary Supplement: Coenzyme Q10

• Registration Number: NCT06040905
• Lead Sponsor: Chung Shan Medical University

Brief Summary

The aim of the study is to investigate the effect of coenzyme Q10 supplementation (150 mg/b.i.d, 300 mg/d, 12 weeks) on coenzyme Q10, glucose parameters, BDNF, myokines, and cognitive function in mild cognitive impairment (MCI) and Alzheimer's disease (AD) patients who combined with hyperglycemia but without sarcopenia, or with hyperglycemia and pre-sarcopenia.

Detailed Description

Alzheimer's disease (AD) is an aging-related disease and is considered to be a type 3 diabetes. Brain-derived neurotrophic factor (BDNF) is a potential therapeutic biomarker for AD. Studies have found that antioxidant supplementation could elevate the level of BDNF. Coenzyme Q10 is an antioxidant nutrient that participates in energy synthesis in mitochondria. Studies have shown that coenzyme Q10 has the potential to regulate blood glucose. However, there are few clinical studies to examine the effects of coenzyme Q10 supplementation on glucose and muscular metabolism and BDNF status in AD. This study will conduct an intervention study to understand the effect of coenzyme Q10 on BDNF and metabolic conditions (hyperglycemia and pre-sarcopenia) in patients with mild cognitive impairment (MCI) and AD. The study will be designed as a randomized, double-blind, cross-over, placebo-controlled study. To investigate the effect of coenzyme Q10 supplementation (150 mg/b.i.d, 300 mg/d, 12 weeks) on coenzyme Q10, glucose parameters, BDNF, myokines, and cognitive function in MCI and AD patients who combined with hyperglycemia but without sarcopenia, or with hyperglycemia and pre-sarcopenia. During the study, demographic data, mini-mental state examination, anthropometric measurements, dietary records, nutritional and muscle function assessment, quality of life, and depression assessment will be collected. Blood specimens will be also collected before and after the intervention; then the levels of coenzyme Q10, BDNF, oxidative stress, antioxidant capacity, myokines, and mitochondrial function will be analyzed. The study hopes to clarify the cause effects of coenzyme Q10 supplementation on the regulation of glucose and muscle metabolism, and cognitive function in this prospective clinical study. The results of this study will provide a reference for aging nutrition and health care.

Study Timeline

• Study First Submitted: 2023-09-04
• Study First Submitted QC: 2023-09-10
• Study First Posted: 2023-09-18
• Study Start: 2023-12-26
• Status Verified: 2024-02
• Last Update Submitted: 2024-02-05
• Last Update Posted: 2024-02-07
• Primary Completion: 2026-07-31
• Study Completion: 2026-07-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• Clinical diagnosis of mild cognitive impairment (MCI).
• Clinical diagnosis of Alzheimer's Disease.
• MCI and AD patients with hyperglycemia ( Fasting glucose >=100 mg/dL).
• MCI and AD patients with pre-sarcopenia (low calf circumference, low hand grip, or low muscle endurance).
• Must be able to swallow tablets.

Exclusion Criteria

• Cancer patients.
• Severe heart, lung, liver, and kidney diseases.
• Severe disability or aphasia.
• Malnutrition (body weight changes > 5% within one month).
• Using coenzyme Q10 supplements.
• Warfarin therapy.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	Placebo (dextrin)
Coenzyme Q10	Coenzyme Q10	Coenzyme Q10 300 mg/day (150 mg/b.i.d.)

Primary Outcome Measures

Name	Time	Method
Insulin	12 weeks	Insulin will measured by chemiluminescence assay.
HbA1C	12 weeks	HbA1C will measured by an automated glycated hemoglobin analyzer.
Brain-derived neurotrophic factor (BDNF)	12 weeks	Sreum BDNF level will measured by huamn BDNF ELISA kit.
Fasting glucose	12 weeks	Fasting glucose will measured by an automated chemistry analyzer.
C-peptide	12 weeks	C-peptide will measured by chemiluminescence assay.
Irisin	12 weeks	Measured by huamn Irisin ELISA kit.
Myostatin	12 weeks	Measured by human myostatin ELISA kit.

Secondary Outcome Measures

Name	Time	Method
Malondialdehyde (MDA) level	12 weeks	MDA will measured by thiobarbituric acid reacting substance.
Advanced Glycation End Products (AGEs) level	12 weeks	AGE level will measured by competitive enzyme-linked immunosorbent assay.
Total antioxidant capacity	12 weeks	Total antioxidant capacity will measured by a Trolox equivalent antioxidant capacity assay.
Mini-Mental State Examination (MMSE) score	12 weeks	The maximum score for the MMSE is 30. A score of 25 or higher is classed as normal. If the score is below 24, the result is usually considered to be abnormal, indicating possible cognitive impairment.
Muscle mass	12 weeks	Muscle mass will measured by (Bioelectrical impedance analysis) BIA menchine.
Hand grip	12 weeks	Hand grip strength will be measured with a grip dynamometer.
Short Physical Performance Battery (SPPB) measurement	12 weeks	SPPB is an objective measurement instrument of balance, lower extremity strength, and functional capacity in older adults. A lower score means low physical fitness.

Trial Locations

Locations (1)

Chung Shan Medical University Hospital; 🇨🇳 Taichung, Taiwan